An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Completed · Phase 2

Conditions studied: Primary Open-Angle Glaucoma, Ocular Hypertension

In brief

This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002. All participants received Bimatoprost Ocular Insert and wore it for approximately 7 months, then had the Insert removed and a new insert placed for another 6 months.

Key facts

Study ID
NCT02143843
Run by
ForSight Vision5, Inc.
People needed
75
Starts
2014-06-05
Expected to finish
2016-01-31
Last updated by the study team
2019-02-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.